Content
09/19/2023
Menlo Park, CA USA
ReCode Therapeutics
completed $50 million Series B Round funding. Investors include
Amgen Ventures, EcoR1 Capital, Leaps by Bayer, MPM BioImpact, OrbiMed Advisors, Osage University Partners, Pfizer Ventures, Sanofi Ventures, Solasta Ventures, Vida Ventures.
About
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
